Option Care Health (NASDAQ:OPCH) Releases Earnings Results, Beats Estimates By $0.01 EPS

Key Points

• Option Care reported Q1 EPS of $0.40, beating estimates by $0.01, but revenue missed at $1.35B versus ~$1.40B and management trimmed FY‑2026 revenue guidance to $5.675B–$5.775B while flagging an approximately $55M gross profit headwind from a CID/Stelara patient reset.
• Despite the revenue cut, management kept full‑year adjusted EBITDA guidance at $480M–$505M and adjusted EPS at $1.82–$1.92, citing cost reductions, improving acute therapies and clinic utilization, and stronger financial flexibility (net leverage ~2.2x, revolver expanded to $850M).
• The stock plunged on heavy volume (down about $6.54 to $20.33) after the release, and multiple plaintiff firms and a securities‑law investigation have opened probes, adding short‑term legal uncertainty.

Option Care Health (NASDAQ:OPCH - Get Free Report) issued its quarterly earnings results on Thursday. The company reported $0.40 EPS for the quarter, topping analysts' consensus estimates of $0.39 by $0.01, FiscalAI reports. Option Care Health had a return on equity of 18.57% and a net margin of 3.67%.The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period in the previous year, the company earned $0.40 earnings per share. The company's quarterly revenue was up 1.3% compared to the same quarter last year. Option Care Health updated its FY 2026 guidance to 1.820-1.920 EPS.

Here are the key takeaways from Option Care Health's conference call:

• The company revised full-year net revenue guidance down to $5.675B–$5.775B (≈1% growth at midpoint) and now expects an approximately $55 million gross profit headwind from the CID/Stelara patient reset.
• Acute therapies and IG‑neuro were strong in Q1 (acute revenue grew high single digits) and ambulatory clinic utilization improved (visits +14% YoY; 34% of nursing visits in suites/clinics), supporting higher-margin growth vectors.
• Management kept full-year adjusted EBITDA guidance at $480M–$505M and adjusted EPS at $1.82–$1.92 despite the revenue cut, citing cost reductions, variable cost discipline, and sequential momentum beginning in Q2.
• Q1 saw a doubling of benefit reverification/reauthorization work that extended into late March, causing a larger-than-expected chronic patient census decline and some patient losses to competitors or self-administration that will take time to recover.
• Financial flexibility improved with net leverage at 2.2x, the revolver expanded to $850M, >$17M of share repurchases in Q1, and continued focus on organic investment and targeted M&A to support recovery and growth.

Option Care Health Price Performance

NASDAQ:OPCH traded down $6.54 during trading hours on Thursday, reaching $20.33. The company had a trading volume of 17,276,087 shares, compared to its average volume of 1,641,903. The stock has a 50-day moving average of $29.45 and a two-hundred day moving average of $30.76. Option Care Health has a one year low of $18.01 and a one year high of $36.80. The firm has a market capitalization of $3.19 billion, a PE ratio of 17.33, a PEG ratio of 1.50 and a beta of 0.95. The company has a quick ratio of 0.96, a current ratio of 1.53 and a debt-to-equity ratio of 0.87.

More Option Care Health News

Here are the key news stories impacting Option Care Health this week:

• Positive Sentiment: Q1 EPS slightly beat consensus: Option Care reported $0.40 EPS vs. consensus ~ $0.39, matching prior‑year EPS — a modest pocket of positive surprise. Q1 Earnings Beat (Zacks)
• Neutral Sentiment: Calls and disclosures available: the company held an earnings call and filed a press release/slide deck with details—useful for parsing management commentary and assumptions behind guidance. Earnings Call Transcript (Seeking Alpha)
• Negative Sentiment: Revenue miss in Q1 and full‑year revenue guidance trimmed: Q1 revenue $1.35B vs. estimates ~$1.40B, and FY‑2026 revenue guide narrowed to ~$5.7–5.8B versus street ~$5.9B — the revenue shortfall and guide cut are the primary catalysts for the selloff. Revenue Miss & Stock Slide (Seeking Alpha)
• Negative Sentiment: Legal/investigator overhang: multiple plaintiff firms and a securities‑law investigation (Holzer & Holzer, Block & Leviton, Johnson Fistel) have announced inquiries tied to the results and guidance, increasing short‑term uncertainty and potential legal costs. Holzer Investigation (GlobeNewswire) Block & Leviton Alert (GlobeNewswire) Johnson Fistel Alert (GlobeNewswire)
• Negative Sentiment: Market reaction and volume: the stock sold off sharply on heavy volume after the release, reflecting investor concern about revenue momentum and the added legal overhang. Market Reaction (Yahoo)

Institutional Trading of Option Care Health

A number of large investors have recently bought and sold shares of OPCH. Advisory Services Network LLC bought a new stake in Option Care Health in the third quarter valued at $35,000. McIlrath & Eck LLC bought a new stake in shares of Option Care Health during the second quarter worth $37,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Option Care Health during the third quarter worth $38,000. Quarry LP grew its holdings in shares of Option Care Health by 502.7% during the third quarter. Quarry LP now owns 1,549 shares of the company's stock worth $43,000 after purchasing an additional 1,292 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in shares of Option Care Health by 528.1% during the second quarter. EverSource Wealth Advisors LLC now owns 1,407 shares of the company's stock worth $46,000 after purchasing an additional 1,183 shares during the last quarter. 98.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on OPCH shares. TD Cowen reiterated a "hold" rating on shares of Option Care Health in a report on Tuesday, January 27th. Citigroup reiterated an "outperform" rating on shares of Option Care Health in a report on Tuesday, January 13th. Truist Financial set a $40.00 target price on Option Care Health in a research note on Tuesday, January 13th. Morgan Stanley upped their target price on Option Care Health from $35.00 to $38.00 and gave the company an "overweight" rating in a research note on Tuesday, January 13th. Finally, Jefferies Financial Group restated a "buy" rating and issued a $37.00 target price on shares of Option Care Health in a research note on Tuesday, January 13th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $37.00.

About Option Care Health

Option Care Health NASDAQ: OPCH is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry's most experienced home infusion businesses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.